The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Open accessAbstract
Effective targeted cancer therapeutic development depends upon distinguishing disease-associated ‘driver’ mutations, which have causative roles in malignancy pathogenesis, from ‘passenger’ mutations, which are dispensable for cancer initiation and maintenance. Translational studies of clinically active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biology. Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approximately 20% of acute myeloid leukaemia (AML) patients and are associated with a poor prognosis. Abundant scientific and clinical evidence, including the lack of convincing clinical activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion. Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was observed in eight of eight FLT3-ITD-positive AML patients with acquired resistance to AC220. Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML. AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Tandem repeats finder: a program to analyze DNA sequences
Benson, G. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.2.573 · Cited by 9,374
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,804
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Aromatic-Aromatic Interaction: A Mechanism of Protein Structure Stabilization
Burley, S. K., & Petsko, G. A. (1985) · Science · doi:10.1126/science.3892686 · Cited by 2,524
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Self-citationThiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Self-citationCrystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Self-citationResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
“Internal tandem duplication (ITD) of key FLT-3 subdomains are validated driver mutations in acute myeloid leukemia, but clinical trials have demonstrated that constant and complete kinase inhibition is required for therapeutic benefit (Grunwald and Levis, 2013; Pratz et al., 2009; Smith et al., 2012).”
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,075
Self-citationBurchert, A., Bug, G., Fritz, L. V., Finke, J., Stelljes, M., Röllig, C., Wollmer, E., Wäsch, R., Bornhäuser, M., Berg, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03345 · Cited by 555
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Li, X., & Song, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00885-3 · Cited by 521
Perl, A. E., Altman, J. K., Cortes, J., Smith, C., Litzow, M., Baer, M. R., Claxton, D., Erba, H. P., Gill, S., Goldberg, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30416-3 · Cited by 490
Self-citationGill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1453 · Cited by 446
“In vitro saturation mutagenesis studies predicted that, due to its activity as a type II kinase inhibitor, on-target mutations in the FLT3 kinase activation loop at D835 or at the gatekeeper residue F691 would generate resistance to quizartinib (8).”
BackgroundSelf-citationA Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer
Cheng, F., Su, L., & Qian, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9453 · Cited by 406
Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia
Klco, J. M., Spencer, D. H., Miller, C. A., Griffith, M., Lamprecht, T. L., O’Laughlin, M., Fronick, C., Magrini, V., Demeter, R. T., Fulton, R. S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.031 · Cited by 395
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., De Bont, E. S. J. M., De Moerloose, B., Dworzak, M., Gibson, B. E. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8289 · Cited by 383
Ravandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-480228 · Cited by 381
Self-citationCortes, J. E., Kantarjian, H., Foran, J. M., Ghirdaladze, D., Zodelava, M., Borthakur, G., Gammon, G., Trone, D., Armstrong, R. C., James, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.8783 · Cited by 361
Self-citationWidespread intron retention diversifies most cancer transcriptomes
Dvinge, H., & Bradley, R. K. (2015) · Genome Medicine · doi:10.1186/s13073-015-0168-9 · Cited by 344
Acute Myeloid Leukemia: A Concise Review
Saultz, J., & Garzon, R. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5030033 · Cited by 342
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Self-citationIntegrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
He, J., Abdel-Wahab, O., Nahas, M. K., Wang, K., Rampal, R. K., Intlekofer, A. M., Patel, J., Krivstov, A., Frampton, G. M., Young, L. E., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664649 · Cited by 311
Towards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Kiyoi, H., Kawashima, N., & Ishikawa, Y. (2020) · Cancer Science · doi:10.1111/cas.14274 · Cited by 298
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lee, L. Y., Hernandez, D., Rajkhowa, T., Smith, S. C., Raman, J. R., Nguyen, B., Small, D., & Levis, M. (2017) · Blood · doi:10.1182/blood-2016-10-745133 · Cited by 280
Self-citationCortes, J., Perl, A. E., Döhner, H., Kantarjian, H., Martinelli, G., Kovacsovics, T., Rousselot, P., Steffen, B., Dombret, H., Estey, E., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30240-7 · Cited by 266
Self-citationMori, M., Kaneko, N., Ueno, Y., Yamada, M., Tanaka, R., Saito, R., Shimada, I., Mori, K., & Kuromitsu, S. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0470-z · Cited by 258
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Galanis, A., Ma, H., Rajkhowa, T., Ramachandran, A., Small, D., Cortes, J., & Levis, M. (2014) · Blood · doi:10.1182/blood-2013-10-529313 · Cited by 252
Self-citationLi, L., Osdal, T., Ho, Y., Chun, S., McDonald, T., Agarwal, P., Lin, A., Chu, S., Qi, J., Li, L., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.08.001 · Cited by 234
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Antar, A. I., Otrock, Z. K., Jabbour, E., Mohty, M., & Bazarbachi, A. (2020) · Leukemia · doi:10.1038/s41375-019-0694-3 · Cited by 243
Shih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.009 · Cited by 236
“FLT3 inhibitors have clinical activity in FLT3ITD mutant AML but do not achieve sustained remission (Kayser and Levis, 2014; Smith et al., 2012).”
BackgroundBurslem, G. M., Song, J., Chen, X., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10320 · Cited by 176
Ferrando, A. A., & López-Otín, C. (2017) · Nature Medicine · doi:10.1038/nm.4410 · Cited by 120
Long, J., Jia, M.-Y., Fang, W.-Y., Chen, X.-J., Mu, L.-L., Wang, Z.-Y., Shen, Y., Xiang, R.-F., Wang, L.-N., Wang, L., et al. (2020) · Blood · doi:10.1182/blood.2019003538 · Cited by 84
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
Leyte-Vidal, A., Garrido Ruiz, D., DeFilippis, R., Leske, I. B., Rea, D., Phan, S., Miller, K. B., Hu, F., Mase, A., Shan, Y., et al. (2024) · Blood · doi:10.1182/blood.2023022538 · Cited by 40
Self-citationmiR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia.
Krakowsky, R. H. E., Wurm, A. A., Gerloff, D., Katzerke, C., Bräuer-Hartmann, D., Hartmann, J.-U., Wilke, F., Thiede, C., Müller-Tidow, C., Niederwieser, D., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0070-y · Cited by 18
Targeting Immune Signaling Pathways in Clonal Hematopoiesis
Azrakhsh, N. A., Mensah-glanowska, P., Sand, K., & Kittang, A. O. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190325100636 · Cited by 8
Metadata
- Authors
- Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., Zarrinkar, P. P., Schadt, E. E., Kasarskis, A., Kuriyan, J., & Shah, N. P.
- Venue
- Nature
- Published
- 2012-04-15
- Volume
- 485
- Issue
- 7397
- Pages
- 260-263
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984209370
- Cited by
- 735
- References
- 30
- FWCI
- 40.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.